GSK Looks To Immuno-Neurology In $700m Alector Tie-up
Return to neuroscience follows activist investor showdown
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
You may also be interested in...
Some big pharma R&D leaders have signaled enhanced interest in neuroscience R&D – and Alzheimer's more specifically – following FDA's approval of Biogen's Aduhelm based on biomarkers.
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.